Cancer-Focused Biotechs ViewRay, Xbiotech Join IPO Rush
Immunotherapy biotech ViewRay Inc. set terms for a $52 million initial public offering Friday, just days after Xbiotech Inc. set terms for a $76 million IPO, as the two cancer-treatment developers...To view the full article, register now.
Already a subscriber? Click here to view full article